Syntopix seals healthcare deal

The Bradford-based group, which was spun out of the University of Leeds, said the unnamed firm will be granted first refusal to negotiate a deal for further development and eventual commercialisation of a compound Syntopix currently has under clinical evaluation.

Syntopix will receive payments throughout the clinical phase.

Syntopix develops compounds which combat skin disorders, oral disease and body odour.

The AIM-listed firm said the deal builds on its key strategy of identifying potential compounds and forming partnerships with leading healthcare and cosmetic companies to bring its products to market.

Last year the firm signed a deal with a consumer healthcare giant to allow it access to its library of compounds. The unnamed firm was given access to Syntopix's library of almost 1,500 compounds.

Chief executive Stephen Jones said: "I am delighted that we have signed this agreement with a global leader in personal care.

"Hygiene and personal care has become increasingly important to consumers and the market opportunity for effective antimicrobials is growing.

"We continue to look forward to working together with our partners to see Syntopix's compounds in well-known consumer brands."